Biotech entity
Of the tracked stories, 1 of 2 also mention Auvelity, the most common co-covered peer. The 22-day window averages about 0.6 stories each week. Each story carries 2 original sources on average, compared with 3.8 for the broader beat in this window.
Last mentioned: Jul 7, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 1 of 2 also mention Auvelity, the most common co-covered peer. The 22-day window averages about 0.6 stories each week. Each story carries 2 original sources on average, compared with 3.8 for the broader beat in this window. At 6, the average consequence score sits below the same-window beat average of 6.4. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. RMC-6236 appears in 2 tracked Biotech stories published from June 16, 2026 through July 7, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 36 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering RMC-6236. Shared-story counts are live from our verified record — not editorial picks.
Moderna flu vaccine PDUFA date
FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
Axsome full-year 2025 results
Annual revenue more than doubles to $617.1 million, with Auvelity net product revenue up 68% year over year.
Revolution Medicines mid-2025 data readout
RMC-6236 shows nearly 90% tumor response in an early-phase pancreatic cancer study, driving stock surge.
Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
Source: The Motley Fool · Adria Cimino
Revolution Medicines' patent infringement claim and a patient death have derailed Erasca's lead candidate, cutting its valuation by $2.8B. The biotech now faces a class action over alleged misrepresentations.
Source: Globenewswire_fr · Benzinga
RMC-6236 is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
